AUTH/3873/01/24: Complainant v Bayer (Eylea website and public access to SmPC) – No breach

📅 2024 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3873/01/24
PartiesComplainant v Bayer plc
ProductEylea (aflibercept)
IssuePublic access to SmPC via Bayer-owned Eylea website patient section (linking to eMC)
Applicable Code year2021
Clauses consideredClause 5.1; Clause 26.2
DecisionNo breach of Clause 5.1; No breach of Clause 26.2
Panel rationale (high level)Clear separation of HCP vs public sections via gateway; supplementary information to Clause 26.2 supports providing SmPC as minimum reference information on public sites
Complaint received24 January 2024
Case completed6 January 2025
AppealNo appeal
SanctionsNone stated (no breach)

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable complainant (self-described health professional) said a patient brought a printout of the Eylea Summary of Product Characteristics (SmPC/SPC).
  • The patient allegedly found it via Google and then via a Bayer-owned Eylea website, using the “patient” option which “prominently” directed to the SmPC.
  • The concern was that the SmPC stated it was “for use by healthcare professionals only” and therefore should not have been accessible from patient pages.
  • Bayer explained the site used an “honesty box” gateway separating UK healthcare professional promotional content from public non-promotional content, and that the public pages linked out to the Electronic Medicines Compendium (eMC) for the patient leaflet and SmPC.
  • Bayer noted the site had a major update on 30 January 2024 (after the complaint) due to a new 8mg dose marketing authorisation, but provided certification for the version relevant to the complaint.
⚖️

Outcome

  • No breach of Clause 26.2.
  • No breach of Clause 5.1.
  • The Panel considered the complainant had not established, on the balance of probabilities, that providing the SPC via a link on patient webpages was inappropriate in the circumstances.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training